-
www.ahrq.gov/hai/cusp/clabsi-neonatal/nclabsi4.html
January 01, 2013 - Eliminating CLABSI, A National Patient Safety Imperative: Neonatal CLABSI Prevention
Results
Previous Page Next Page
Table of Contents
Eliminating CLABSI, A National Patient Safety Imperative: Neonatal CLABSI Prevention
Executive Summary
Introduction & Objectives
Methods
Data Collection and …
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/zk8YxjaQxLGUTtt__nBQB_
September 09, 2021 - Depression and Suicide Risk Screening: Updated Evidence Summary and Systematic Review for the US Preventive Services Task Force
Depression and Suicide Risk Screening
Updated Evidence Report and Systematic Review
for the US Preventive Services Task Force
Elizabeth A. O’Connor, PhD; Leslie A. Perdue, MPH; Erin L. Coppo…
-
effectivehealthcare.ahrq.gov/sites/default/files/Evidence%20Summary_2.pdf
May 01, 2020 - CER 226: Evidence summary_Labor Dystocia
Purpose of Review
To review the evidence on the definition of
“normal” labor progression and the comparative
effectiveness of different strategies for treating
labor dystocia in women with otherwise
uncomplicated pregnancies. Strategies assessed
include amniotomy, suppo…
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/Evidence%20Summary_2.pdf
May 01, 2020 - CER 226: Evidence summary_Labor Dystocia
Purpose of Review
To review the evidence on the definition of
“normal” labor progression and the comparative
effectiveness of different strategies for treating
labor dystocia in women with otherwise
uncomplicated pregnancies. Strategies assessed
include amniotomy, suppo…
-
effectivehealthcare-admin.ahrq.gov/products/insulin-blood-sugar-2010/research-protocol
December 01, 2019 - Skip to main content
An official website of the Department of Health & Human Services
Careers
Contact Us
Español
FAQs
Effective Health Care Program
Powered by the Evidence-based Practice Centers
…
-
www.uspreventiveservicestaskforce.org/uspstf/recommendation/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis
August 22, 2023 - fumarate alone and placebo in pregnancy rate, risk of preterm birth, congenital anomalies, or postpartum infant … mortality. 46 There were no differences between the dapivirine vaginal ring and placebo in incidence
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/6fFns4N2J-t5EGC5BUdRuu
October 23, 2023 - marate alone and placebo in pregnancy rate, risk of preterm birth,
congenital anomalies, or postpartum infant … mortality.46 There were
no differences between the dapivirine vaginal ring and placebo in
incidence
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/MWRHULpw6y_5Uk_KXTyvp8
January 10, 2017 - Folic Acid Supplementation for the Prevention of Neural Tube Defects: An Updated Evidence Report and Systematic Review
Copyright 2016 American Medical Association. All rights reserved.
Folic Acid Supplementation for the Prevention
of Neural Tube Defects
An Updated Evidence Report and Systematic Review
for the US Pre…
-
www.ahrq.gov/sites/default/files/2024-09/rogers-report.pdf
January 01, 2024 - Final Progress Report: Staff Nurse Fatigue and Patient Safety
Staff Nurse Fatigue and Patient Safety
Principal Investigator: Ann E. Rogers, PhD, RN
Co-Investigators: Linda Aiken, PhD, RN
David Dinges, PhD
Wei-ting Hwang, PhD
Linda D. Scott, PhD, RN
Organization: University of Pennsylvania School of Nursi…
-
www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary/chlamydia-and-gonorrhea-screening
September 14, 2021 - Share to Facebook
Share to X
Share to WhatsApp
Share to Email
Print
Evidence Summary
Chlamydia and Gonorrhea: Screening
September 14, 2021
Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as …
-
hcup-us.ahrq.gov/reports/statbriefs/sb193-Neonatal-Maternal-Hospitalizations-Substance-Use.jsp
July 01, 2015 - Neonatal and Maternal Hospital Stays Related to Substance Use, 2006-2012 #193
An official website of the Department of Health & Human Services
Search All AHRQ Websites
Careers
Contact Us
…
-
ce.effectivehealthcare.ahrq.gov/sites/default/files/2024-01/bates-report.pdf
January 01, 2024 - Final Progress Report: Improving Medication Safety Across Clinical Settings
FINAL REPORT: November 29, 2007
Improving Medication Safety Across Clinical Settings
Principal Investigator: David W. Bates; dbates@…
-
www.ahrq.gov/sites/default/files/2024-01/bates-report.pdf
January 01, 2024 - Final Progress Report: Improving Medication Safety Across Clinical Settings
FINAL REPORT: November 29, 2007
Improving Medication Safety Across Clinical Settings
Principal Investigator: David W. Bates; dbates@…
-
www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/duration/chipra-154-fullreport.pdf
July 01, 2018 - Continuity of Insurance: Coverage Presumed Eligible
1
Continuity of Insurance: Coverage Presumed Eligible
Section 1. Basic Measure Information
1.A. Measure Name
Continuity of Insurance: Coverage Presumed Eligible
1.B. Measure Number
0154
1.C. Measure Description
Please provide a non-technical descripti…
-
www.innovations.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/duration/chipra-155-fullreport.pdf
September 01, 2018 - Continuity of Insurance: Coverage Presumed Ineligible
1
Continuity of Insurance: Coverage Presumed
Ineligible
Section 1. Basic Measure Information
1.A. Measure Name
Continuity of Insurance: Coverage Presumed Ineligible
1.B. Measure Number
0155
1.C. Measure Description
Please provide a non-technical d…
-
www.healthcare411.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/duration/chipra-155-fullreport.pdf
September 01, 2018 - Continuity of Insurance: Coverage Presumed Ineligible
1
Continuity of Insurance: Coverage Presumed
Ineligible
Section 1. Basic Measure Information
1.A. Measure Name
Continuity of Insurance: Coverage Presumed Ineligible
1.B. Measure Number
0155
1.C. Measure Description
Please provide a non-technical d…
-
www.innovations.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/duration/chipra-156-fullreport.pdf
June 01, 2018 - Continuity of Insurance: Duration of First Observed Enrollment
1
Continuity of Insurance: Duration of First Observed
Enrollment
Section 1. Basic Measure Information
1.A. Measure Name
Continuity of Insurance: Duration of First Observed Enrollment
1.B. Measure Number
0156
1.C. Measure Description
Please …
-
www.healthcare411.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/duration/chipra-156-fullreport.pdf
June 01, 2018 - Continuity of Insurance: Duration of First Observed Enrollment
1
Continuity of Insurance: Duration of First Observed
Enrollment
Section 1. Basic Measure Information
1.A. Measure Name
Continuity of Insurance: Duration of First Observed Enrollment
1.B. Measure Number
0156
1.C. Measure Description
Please …
-
www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/duration/chipra-156-fullreport.pdf
June 01, 2018 - Continuity of Insurance: Duration of First Observed Enrollment
1
Continuity of Insurance: Duration of First Observed
Enrollment
Section 1. Basic Measure Information
1.A. Measure Name
Continuity of Insurance: Duration of First Observed Enrollment
1.B. Measure Number
0156
1.C. Measure Description
Please …
-
www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/duration/chipra-153-fullreport.pdf
May 23, 2018 - Continuity of Insurance: Informed Participation
1
Continuity of Insurance: Informed Participation
Section 1. Basic Measure Information
1.A. Measure Name
Continuity of Insurance: Informed Participation
1.B. Measure Number
0153
1.C. Measure Description
Please provide a non-technical description of the me…